asenapine
Megjelenés
| Clinical data | |
|---|---|
| Trade names | Saphris, Sycrest, Secuado |
| Other names | ORG-5222 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a610015 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Sublingual, transdermal |
| Drug class | Atypical antipsychotic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 35% (sublingual), <2% (oral), |
| Protein binding | 95% |
| Metabolism | hepatic (glucurinodation by UGT1A4 and oxidative metabolism by CYP1A2) |
| Elimination half-life | 24 hours (sublingual), |
| Excretion | Kidney (50%), Faecal (40%; ~5–16% as unchanged drug in faeces) |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI |
|
| ChEMBL |
|
| Chemical and physical data | |
| Formula | C17H16ClNO |
| Molar mass | 285.771 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Főnév
asenapine (tsz. asenapines)